Home » Diabetes, new system for the automatic administration of insulin

Diabetes, new system for the automatic administration of insulin

by admin

ROME (ITALPRESS) – Diabetes is a disease that affects the daily life of the people who suffer from it and requires constant monitoring and continuous therapeutic attention. The difficult management of this disease and, in particular, of insulin therapy, means that over 7 out of 10 people with type 1 diabetes do not achieve good glycemic control.1 “Despite advances in therapies, with increasingly performing insulins , and devices with advanced technologies, only 30 percent of people with type 1 diabetes have glycated hemoglobin values ​​below 7 percent according to data from the 2020 Annals and among those who do not reach the desired target, as much as 35 percent it is frankly decompensated, with glycated hemoglobin values ​​higher than 8 percent “, says Paola Ponzani, medical director in charge of the SSD Diabetology and Metabolic Diseases ASL 4 Chiavarese (GE). From today, it is also available in Italy, for doctors and people with type 1 diabetes, DBLG1 System, a new hybrid closed loop system for the automatic administration of insulin (AID), which allows to significantly facilitate the management of diabetes by improving clinical results, thanks to the integration of the Accu-Chek Insight pump, the Dexcom G6 continuous glucose monitoring system and the DBLG1 algorithm inserted in a portable device. “The closed loop hybrid systems mark an important step forward in the evolution towards the artificial pancreas, allowing the automatic delivery of insulin day and night, in response to the glycemic values ​​detected by the sensor, with the request for intervention of the patient only at the moment. of the meal, when he has to enter the quantity of carbohydrates taken – explains Ponzani -. From a clinical point of view, these systems, based on the use of artificial intelligence algorithms, allow to keep the patient longer inside the glycemic range considered at target, ie between 70 and 180 mg / dl, to reduce glycemic variability and, above all, hypoglycemia “. “For a person with diabetes – he continues – this means an improvement in their well-being and quality of life, both for the lower risk of hypoglycemia and for a reduction in weight that involves managing their disease, but in the long term it implies also a reduction in the risk of complications thanks to better metabolic compensation “. “Thanks to the three elements that make up the DBLG1 System, the insulin is automatically delivered through the pump based on the processing done in real time by the algorithm that receives the glucose measurements from the sensor and on the basis of the data entered by the patient. The DBLG1 algorithm calculates the correct amount of insulin to be delivered, adjusts the rate of basal insulin or administers an automatic correction bolus when necessary – explains Serena Ferrari, Marketing Director Roche Diabetes Care Italy -. DBLG1 System has been shown to increase the time that a person with diabetes remains in the correct glycemic range, compared to a system without this type of algorithm, promising a significant improvement in the quality of life “. “Furthermore, the algorithm is equipped with a machine learning system, that is – Ferrari points out – which learns from events that occur, for example, in conjunction with meals and physical activity and which allows it to predict the glycemic trend by suggesting the necessary insulin corrections “. The system, in addition to being customizable through parameters identified together with your doctor, allows you to transmit and store the measurements taken, on the YourLoops web platform, where both the doctor and the patient can view the data, thus allowing an optimization of the visit and the possibility of remote patient management. “Clinical studies on DBLG1 – continues Paola Ponzani – have shown very promising results. In particular, an increase of 10 per cent, which is equivalent to about 2 hours a day, in the time spent by the patient in the target range and a reduction was observed. of 2 percent of the time spent in hypoglycemia, or 30 minutes less per day. In my experience these results confirm the positive impact this system has on the quality of life of my patients “. “DBLG1 System is the first but not the only example of Roche Diabetes Care’s Vision based on the implementation of Integrated Personalized Diabetes Management (iPDM), which allows you to customize diabetes management to the real needs of patients, in to offer them real relief from the disease through the development of connected digital devices, services and products – says Rodrigo Diaz de Vivar Wacher, CEO Roche Diabetes Care Italy -. The holistic approach of the iPDM is based on an open ecosystem that promotes collaboration with all stakeholders and allows us to combine our solutions and the solutions of our partners “. “In this – he concludes – DBGL1 System is the result of the partnership between various companies and is a clear sign of our commitment to openly collaborate in order to pursue this Vision linked to the iPDM. As Roche, we are therefore proud to be able to commit ourselves daily in projects as ambitious as DBLG1 System that want to bring real relief to all people with diabetes, wherever they are “. (ITALPRESS). fsc / com 27-May-21 15:06

See also  Covid: in Puglia 14 deaths and 5,578 new cases, 18% of tests

COPYRIGHT today © breaking latest news

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy